Floatz logo

PROPRANOLOL

Immunotherapy

Sun Yat-sen UniversitySmall moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

69 Active assets in the Immunotherapy cohort.

Asset / SponsorPhaseRating
Serplulimab
Tao Zhang
Phase 3BB
Pembrolizumab
Ismail Gögenur
Phase 4BB
LENVATINIB
The First Affiliated Hospital with Nanjing Medical University
Phase 4BB
Rivoceranib
Fudan University
Phase 3B
Nivolumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4B

View all 50 →

Same molecule, other indications

PROPRANOLOL is also rated in:

migraine disorderDormant
BBB
Indicative ·
74 / 100
View asset →
esophageal varicesDormant
BBB
Indicative ·
74 / 100
View asset →
esophageal varices with bleedingDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →